Citations

Clear

4610 citation(s) found for "Lu, Brian".

Reliability of 3-Dimensional Measures of Single-Leg Cross Drop Landing Across 3 Different Institutions
DiCesare, Christopher A. , Bates, Nathaniel A. , Foss, Kim D. Barber , Thomas, Staci , Wordeman, Samuel C., Sugimoto, Dai , Roewer, Benjamin D., McKeon, Jennifer M. Medina, Stasi, Stephanie Di , Noehren, Brian , Ford, Kevin R. , Kiefer, Adam W. , Hewett, Timothy E. , Myer, Gregory D. , Bates, Nathaniel A

Mayo Clinic

Orthopaedic Journal of Sports Medicine | December 30, 2015 | Volume: 3 | Issue: 12 | Pages: No page available

10.1177/2325967115617905 | PMID 26779550 Get It

Background: Anterior cruciate ligament (ACL) injuries are physically and financially devastating but affect a relatively small percentage of the population. Prospective identification of risk factors for ACL injury necessitates a large sample size; therefore, study of this injury would benefit from a multicenter approach. Purpose: To determine the reliability of kinematic and kinetic measures of a single-leg cross drop task across 3 institutions. Study Design: Controlled laboratory study. Methods: Twenty-five female high school volleyball players participated in this study. Three-dimensional motion data of each participant performing the single-leg cross drop were collected at 3 institutions over a period of 4 weeks. Coefficients of multiple correlation were calculated to assess the reliability of kinematic and kinetic measures during the landing phase of the movement. Results: Between-centers reliability for kinematic waveforms in the frontal and sagittal planes was good, but moderate in the transverse plane. Between-centers reliability for kinetic waveforms was good in the sagittal, frontal, and transverse planes. Conclusion: Based on these findings, the single-leg cross drop task has moderate to good reliability of kinematic and kinetic measures across institutions after implementation of a standardized testing protocol. Clinical Relevance: Multicenter collaborations can increase study numbers and generalize results, which is beneficial for studies of relatively rare phenomena, such as ACL injury. An important step is to determine the reliability of risk assessments across institutions before a multicenter collaboration can be initiated.
Discriminating long myelitis of neuromyelitis optica from sarcoidosis
Flanagan, Eoin P. , Krecke, Karl N. , Aksamit, Allen J. , Pittock, Sean J. , Weinshenker, Brian G. , Pittock, S J , Kaufmann, Timothy J. , Keegan, B. Mark , Giannini, Caterina , Flanagan, E P , Weinshenker, Brian G

Mayo Clinic

Annals of Neurology | December 17, 2015 | Volume: 79 | Issue: 3 | Pages: 437-447

10.1002/ana.24582 | PMID 26677112 Get It

ObjectiveTo compare longitudinally extensive myelitis in neuromyelitis optica spectrum disorders (NMOSD) and spinal cord sarcoidosis (SCS).MethodsWe identified adult patients evaluated between 1996 and 2015 with SCS or NMOSD whose first myelitis episode was accompanied by a spinal cord lesion spanning ≥3 vertebral segments. All NMOSD patients were positive for aquaporin‐4–immunoglobulin G, and all sarcoidosis cases were pathologically confirmed. Clinical characteristics were evaluated. Spine magnetic resonance imaging was reviewed by 2 neuroradiologists.ResultsWe studied 71 patients (NMOSD, 37; SCS, 34). Sixteen (47%) SCS cases were initially diagnosed as NMOSD or idiopathic transverse myelitis. Median delay to diagnosis was longer for SCS than NMOSD (5 vs 1.5 months, p < 0.01). NMOSD myelitis patients were more commonly women, had concurrent or prior optic neuritis or intractable vomiting episodes more frequently, had shorter time to maximum deficit, and had systemic autoimmunity more often than SCS (p < 0.05). SCS patients had constitutional symptoms, cerebrospinal fluid (CSF) pleocytosis, and hilar adenopathy more frequently than NMOSD (p < 0.05); CSF hypoglycorrhachia (11%, p = 0.25) and elevated angiotensin‐converting enzyme (18%, p = 0.30) were exclusive to SCS. Dorsal cord subpial gadolinium enhancement extending ≥2 vertebral segments and persistent enhancement >2 months favored SCS, and ringlike enhancement favored NMOSD (p < 0.05). Maximum disability was similar in both disorders.InterpretationSCS is an under‐recognized cause of longitudinally extensive myelitis that commonly mimics NMOSD. We identified clinical, laboratory, systemic, and radiologic features that, taken together, help discriminate SCS from NMOSD. ANN NEUROL 2016;79:437–447
Genome-Wide Association Studies in Primary Biliary Cirrhosis
Gulamhusein, Aliya , Juran, Brian D., Gulamhusein, Aliya F, Lazaridis, Konstantinos N. , Lazaridis, Konstantinos

Mayo Clinic

Seminars in Liver Disease | December 16, 2015 | Volume: 35 | Issue: 04 | Pages: 392-401

10.1055/s-0035-1567831 | PMID 26676814 Get It

Atypical cartilaginous tumor/chondrosarcoma, grade 1, of the mastoid in three family members: A new entity
Frisch, Christopher D., Inwards, Carrie Y., Lalich, Ian J. , Carter, Jodi M. , Neff, Brian A., Carter, Jodi

Mayo Clinic

The Laryngoscope | December 15, 2015 | Volume: 126 | Issue: 9 | Pages: E310-E313

10.1002/lary.25802 | PMID 26667047 Get It

O2‐01‐03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence
Tang, Mengxuan , Owen, Christopher J. , Su, Yi , Hornbeck, Russ C. , Stevenson, Trish A., Cash, Lisa, Raichle, Marcus E., Preboske, Gregory M., Xiong, Chengjie , Moulder, Krista L., Buckles, Virginia, Joseph‐Mathurin, Nelly , Friedrichsen, Karl A. , Raichle, Marcus E. , Gordon, Brian A. , Koeppe, Robert A. , Jack, Clifford R. , Goate, Alison , Cruchaga, Carlos , Bateman, Randall J. , Morris, John C. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2015.07.132 Get It

IC‐P‐051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence
Tang, Mengxuan , Owen, Christopher J. , Hornbeck, Russ C. , Stevenson, Trish A., Cash, Lisa, Raichle, Marcus E. , Preboske, Gregory M., Xiong, Chengjie , Moulder, Krista L., Buckles, Virginia, Joseph‐Mathurin, Nelly , Friedrichsen, Karl A. , Su, Yi , Gordon, Brian A. , Koeppe, Robert A. , Jack, Clifford R. , Goate, Alison , Cruchaga, Carlos , Bateman, Randall J. , Morris, John C. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2015.06.072 Get It

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
Cree, Bruce , Bennett, Jeffrey L. , Sheehan, Mark , Hartung, Hans-Peter, Aktaş, Orhan , Kim, Ho Jin , Paul, Friedemann , Pittock, Sean J, Weinshenker, Brian G. , Wingerchuk, Dean M. , Cutter, Gary , Patra, Kaushik, Flor, Armando , Barron, Gerard, Madani, Soraya, Ratchford, John N. , Katz, Eliezer , Pittock, Sean J. , Wingerchuk, Dean, Pittock, S J , Cohen, Jeffrey Allen , Fujihara, Kazuo , Bennett, Jeffrey L , Weinshenker, Brian G , Cree, Bruce Ac , Paul, Friedemann

Mayo Clinic

Multiple Sclerosis Journal | December 14, 2015 | Volume: 22 | Issue: 7 | Pages: 862-872

10.1177/1352458515620934 | PMID 26666258 Get It

Background: To date, no treatment for neuromyelitis optica (NMO) has been granted regulatory approval, and no controlled clinical studies have been reported. Objective: To design a placebo-controlled study in NMO that appropriately balances patient safety and clinical–scientific integrity. Methods: We assessed the “standard of care” for NMO to establish the ethical framework for a placebo-controlled trial. We implemented measures that balance the need for scientific robustness while mitigating the risks associated with a placebo-controlled study. The medical or scientific community, patient organizations, and regulatory authorities were engaged early in discussions on this placebo-controlled study, and their input contributed to the final study design. Results: The N-MOmentum study (NCT02200770) is a clinical trial that randomizes NMO patients to receive MEDI-551, a monoclonal antibody that depletes CD19+ B-cells, or placebo. The study design has received regulatory, ethical, clinical, and patient approval in over 100 clinical sites in more than 20 countries worldwide. Conclusion: The approach we took in the design of the N-MOmentum trial might serve as a roadmap for other rare severe diseases when there is no proven therapy and no established clinical development path.
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine
Burns, Ted M., Smith, Gordon, Allen, Jeffrey A. , Amato, Anthony A. , Arnold, W. David , Barohn, Richard J., Benatar, Michael , Bird, Shawn J. , Bromberg, Mark B. , Chahin, Nizar, Ciafaloni, Emma , Corse, Andrea M. , David, William S., Dimberg, Elliot L., Sousa, De , Donofrio, Peter D., Dyck, P. James B. , Engel, Andrew G. , Ensrud, Erik , Ferrante, Mark A., Freimer, Miriam , Gable, Karissa , Gibson, Summer, Gilchrist, James M. , Goldstein, Jonathan , Gooch, Clifton L. , Goodman, Brent P., Gorelov, Dmitri, Gospe, Sídney M. , Goyal, Namita , Guidon, Amanda C. , Guptill, Jeffrey T. , Gutmann, Laurie , Gutmann, Ludwig , Gwathmey, Kelly , Harati, Yadollah, Harper, C. Michel , Hehir, Michael K. , Hobson‐Webb, Lisa D., Howard, James F. , Jackson, Carlayne E. , Jones, Sarah , Juel, Vern C. , Kaminski, Henry J. , Kennelly, Kathleen D., Khella, Sami, Khoury, Julie, Kincaid, John C., Kissel, John T., Kolb, Noah , Lacomis, David , Larriviere, Daniel G., Lewis, Richard A. , Litchy, William J. , Logigian, Eric L. , Lou, Jau-Shin, MacGowen, Daniel J.L., Maselli, Ricardo A. , Massey, Janice M., Mauermann, Michelle L. , Mathews, Katherine D. , Meriggioli, Matthew N. , Moon, Joon-Shik, Mozaffar, Tahseen , Nations, Sharon , Ostrow, Lyle W. , Pascuzzi, Robert M. , Peltier, Amanda , Ruzhansky, Katherine , Ross, Mark A., Rubin, Devon I., Russell, James A., Sachs, George, Salajegheh, Mohammad, Saperstein, David , Scelsa, Stephen N. , Selcen, Duygu , Shaibani, Aziz , Silvestri, Nicholas J. , Singleton, J. Rob, Smith, Benn E., So, Yuen T., Solórzano, Guillermo, Sorenson, Eric J. , Srinivasen, Jayashri, Tavee, Jinny , Tawil, Rabi , Thaisetthawatkul, Pariwat , Thornton, Charles A. , Trivedi, Jaya , Vernino, Steven , Wang, Annabel K., Webb, Tyler A., Weiss, Michael D. , Windebank, Anthony J. , Wolfe, Gil I. , Crum, Brian A. , Dimberg, Elliot, Chahin, Nizar, Cohen, Jeffrey Allen , Johnson, Nicholas E , Karam, Chafic , Ladha, Shafeeq , Li, Yuebing , Miller, Robert G. , Nowak, Richard J. , Richman, David P. , Shieh, Perry B. , Kolb, Noah A , Mauermann, Michelle L , Gutmann, Laurie , Allen, Jeffrey A , Arnold, W David , Vernino, Steven , Kaminski, Henry

Mayo Clinic

Muscle & Nerve | December 13, 2015 | Volume: 53 | Issue: 2 | Pages: 165-168

10.1002/mus.25009 | PMID 26662952 Get It

Evaluation of Matrix-Assisted Laser Desorption Ionization−Time of Flight Mass Spectrometry for Identification of Mycobacterium species, Nocardia species, and Other Aerobic Actinomycetes
Buckwalter, Seanne P., Olson, Sara L., Connelly, Brian J., Lucas, Beatriz Cacciacarro, Rodning, Amanda A, Walchak, Robert C., Deml, Sharon M., Wohlfiel, Sherri L., Wengenack, Nancy L.

Mayo Clinic

Journal of Clinical Microbiology | December 4, 2015 | Volume: 54 | Issue: 2 | Pages: 376-384

10.1128/jcm.02128-15 | PMID 26637381 Get It

ABSTRACT The value of matrix-assisted laser desorption ionization−time of flight mass spectrometry (MALDI-TOF MS) for the identification of bacteria and yeasts is well documented in the literature. Its utility for the identification of mycobacteria and Nocardia spp. has also been reported in a limited scope. In this work, we report the specificity of MALDI-TOF MS for the identification of 162 Mycobacterium species and subspecies, 53 Nocardia species, and 13 genera (totaling 43 species) of other aerobic actinomycetes using both the MALDI-TOF MS manufacturer's supplied database(s) and a custom database generated in our laboratory. The performance of a simplified processing and extraction procedure was also evaluated, and, similar to the results in an earlier literature report, our viability studies confirmed the ability of this process to inactivate Mycobacterium tuberculosis prior to analysis. Following library construction and the specificity study, the performance of MALDI-TOF MS was directly compared with that of 16S rRNA gene sequencing for the evaluation of 297 mycobacteria isolates, 148 Nocardia species isolates, and 61 other aerobic actinomycetes isolates under routine clinical laboratory working conditions over a 6-month period. MALDI-TOF MS is a valuable tool for the identification of these groups of organisms. Limitations in the databases and in the ability of MALDI-TOF MS to rapidly identify slowly growing mycobacteria are discussed.
Syntactic and semantic errors in radiology reports associated with speech recognition software
Ringler, Michael D. , Goss, Brian C., Bartholmai, Brian J. , Bartholmai, Brian J

Mayo Clinic

Health Informatics Journal | December 3, 2015 | Volume: 23 | Issue: 1 | Pages: 3-13

10.1177/1460458215613614 | PMID 26635322 Get It

Speech recognition software can increase the frequency of errors in radiology reports, which may affect patient care. We retrieved 213,977 speech recognition software–generated reports from 147 different radiologists and proofread them for errors. Errors were classified as “material” if they were believed to alter interpretation of the report. “Immaterial” errors were subclassified as intrusion/omission or spelling errors. The proportion of errors and error type were compared among individual radiologists, imaging subspecialty, and time periods. In all, 20,759 reports (9.7%) contained errors, of which 3992 (1.9%) were material errors. Among immaterial errors, spelling errors were more common than intrusion/omission errors ( p < .001). Proportion of errors and fraction of material errors varied significantly among radiologists and between imaging subspecialties ( p < .001). Errors were more common in cross-sectional reports, reports reinterpreting results of outside examinations, and procedural studies (all p < .001). Error rate decreased over time ( p < .001), which suggests that a quality control program with regular feedback may reduce errors.